12/28/2012

Aura Biosciences secured $3.2 million in the second tranche of a Series A funding round from investors including Henri Termeer, a former president of Genzyme. The Mass.-based biotech focuses on developing pseudo-viruses for treatment of cancer.

Related Summaries